Visceral adipose tissue (VAT), the fat stored within the abdominal cavity surrounding internal organs, has emerged as a critical determinant of metabolic health. Unlike subcutaneous adipose tissue (SAT), VAT is metabolically active, secreting pro-inflammatory cytokines and free fatty acids that contribute to insulin resistance, type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). Recent years have witnessed significant breakthroughs in understanding the molecular underpinnings of VAT accumulation, its pathological remodeling, and novel therapeutic strategies. This review highlights key advances in VAT research, focusing on cellular heterogeneity, epigenetic regulation, imaging technologies, and emerging pharmacological interventions.

1. Cellular and Molecular Heterogeneity of Visceral Fat

A landmark achievement in VAT research has been the application of single-cell RNA sequencing (scRNA-seq) to map the cellular landscape of human adipose tissue. A 2023 study by Emont et al. published inCell Metabolismidentified distinct adipocyte subtypes in VAT compared to SAT, revealing that visceral adipocytes exhibit a unique gene expression profile enriched for pro-fibrotic and inflammatory pathways (Emont et al., 2023). Specifically, a population of "dysfunctional" adipocytes in VAT was found to overexpress genes such asCOL6A3andTGFB1, promoting extracellular matrix remodeling and fibrosis, which in turn impairs adipocyte expandability and exacerbates metabolic dysfunction.

Furthermore, the role of immune cells within VAT has been redefined. Macrophage polarization in VAT is skewed toward a pro-inflammatory M1-like phenotype, driven by local lipid accumulation and hypoxia. Recent work by Weisberg et al. (2024) demonstrated that visceral adipose tissue macrophages (ATMs) exhibit a unique metabolic signature characterized by increased glycolysis and succinate accumulation, which activates HIF-1α and perpetuates inflammation. Targeting succinate receptor SUCNR1 in ATMs has shown promise in reducing VAT inflammation in murine models, suggesting a potential therapeutic avenue.

2. Epigenetic and Developmental Programming of VAT

The developmental origins of visceral obesity have gained attention, with studies highlighting the role of epigenetic modifications during critical windows. A 2024 study inNature Communicationsby Zhang et al. identified that early-life exposure to a high-fat diet induces persistent DNA methylation changes at theHOXA5locus in visceral preadipocytes, leading to enhanced adipogenic capacity and increased VAT mass in adulthood (Zhang et al., 2024). This programming effect was partially reversible by maternal exercise, underscoring the potential for early intervention.

Additionally, the long non-coding RNA (lncRNA)HOTAIRhas been implicated in VAT-specific adipogenesis. Knockdown ofHOTAIRin human visceral preadipocytes reduced lipid accumulation and expression of key adipogenic genes such asPPARGandCEBPA, while its overexpression in subcutaneous preadipocytes induced a visceral-like phenotype (Li et al., 2023). These findings highlight the existence of a "visceral fat identity" encoded at the epigenetic level, opening new doors for targeted modulation.

3. Technological Breakthroughs in VAT Quantification and Imaging

Accurate assessment of VAT volume and distribution is essential for risk stratification. Traditional methods like dual-energy X-ray absorptiometry (DXA) and computed tomography (CT) have been complemented by advanced magnetic resonance imaging (MRI) techniques. A 2024 study by Linge et al. inRadiologyvalidated a deep learning algorithm that automatically segments VAT from whole-body MRI scans with high precision, reducing analysis time from hours to minutes (Linge et al., 2024). This technology enables large-scale epidemiological studies and clinical trials to track VAT changes with unprecedented granularity.

Moreover, the development of positron emission tomography (PET) tracers targeting fibroblast activation protein (FAP) has allowed non-invasive visualization of VAT fibrosis. A pilot study by Ebert et al. (2024) demonstrated that FAP-PET signal intensity correlates with histological fibrosis scores and predicts future metabolic deterioration in obese individuals, offering a novel biomarker for early intervention.

4. Therapeutic Advances: Pharmacological and Lifestyle Interventions

The glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, have demonstrated remarkable efficacy in reducing VAT. A secondary analysis of the STEP 1 trial showed that semaglutide led to a 30% reduction in VAT area over 68 weeks, independent of total weight loss (Wilding et al., 2023). More recently, the combination of GLP-1 and amylin analogues (e.g., cagrilintide/semaglutide) has shown synergistic effects, with a 2024 phase 2 trial reporting a 32% reduction in VAT compared to placebo, accompanied by improvements in hepatic steatosis and insulin sensitivity.

Beyond pharmacotherapy, the role of exercise modality in VAT reduction has been refined. A 2024 meta-analysis by Ismail et al. found that high-intensity interval training (HIIT) is superior to moderate-intensity continuous training (MICT) for VAT loss, even when total energy expenditure is matched. Mechanistically, HIIT enhances catecholamine-induced lipolysis in VAT and upregulates beta-3 adrenergic receptor expression, promoting fat oxidation.

5. Future Perspectives

The future of VAT research lies in precision medicine. Integrating multi-omics data (genomics, epigenomics, proteomics) with imaging biomarkers will enable personalized risk prediction and targeted interventions. The development of orally available small molecules that selectively inhibit VAT-specific adipogenesis, such as those targeting theHOXA5pathway, is on the horizon. Additionally, the gut microbiota–VAT axis is emerging as a key regulator; fecal microbiota transplantation from lean donors has been shown to reduce VAT in metabolic syndrome patients, though larger trials are needed.

In conclusion, the past five years have transformed our understanding of visceral fat from a passive energy depot to a dynamic, pathogenic organ. Advances in single-cell biology, epigenetic reprogramming, imaging technology, and pharmacotherapy are converging to offer new hope for combating visceral obesity and its metabolic consequences.

References